(Q33887356)

29 July 2017

1 reference

title

Inhibitors of the kynurenine pathway (English)

1 reference

29 July 2017

Stone TW

1

0 references

publication date

1 February 2000

1 reference

European Journal of Medicinal Chemistry

29 July 2017

1 reference

29 July 2017

35

1 reference

29 July 2017

179-186

1 reference

29 July 2017

2

1 reference

Quinolinic acid: a potent endogenous excitant at amino acid receptors in CNS

29 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900121-5

7 January 2021

Quinolinic acid: regional variations in neuronal sensitivity

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900121-5

7 January 2021

Excitant activity of methyl derivatives of quinolinic acid on rat cortical neurones

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900121-5

7 January 2021

An iontophoretic investigation of the actions of convulsant kynurenines and their interaction with the endogenous excitant quinolinic acid.

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900121-5

7 January 2021

Quinolinic acid and other kynurenines in the central nervous system

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900121-5

7 January 2021

NMDA receptors and ligands in the vertebrate CNS.

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900121-5

7 January 2021

Glycine potentiates the NMDA response in cultured mouse brain neurons

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900121-5

7 January 2021

Kynurenic acid antagonises responses to NMDA via an action at the strychnine-insensitive glycine receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900121-5

7 January 2021

Actions of excitatory amino acids and kynurenic acid in the primate hippocampus: a preliminary study.

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900121-5

7 January 2021

Sensitivity of hippocampal neurones to kainic acid, and antagonism by kynurenate

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900121-5

7 January 2021

Suppression of ictal-like activity by kynurenic acid does not correlate with its efficacy as an NMDA receptor antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900121-5

7 January 2021

Comparison of kynurenic acid and 2-APV suppression of epileptiform activity in rat hippocampal slices.

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900121-5

7 January 2021

Effects of central and peripheral administration of kynurenic acid on hippocampal evoked responses in vivo and in vitro.

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900121-5

7 January 2021

Inhibition of excitatory neurotransmission with kynurenate reduces brain edema in neonatal anoxia.

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900121-5

7 January 2021

Kynurenate inhibition of cell excitation decreases stroke size and deficits

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900121-5

7 January 2021

4-[(Carboxymethyl)oxy]- and 4-[(carboxymethyl)amino]-5,7-dichloroquinoline-2-carboxylic acid: new antagonists of the strychnine-insensitive glycine binding site on the N-methyl-D-aspartate receptor complex.

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900121-5

7 January 2021

Kynurenic acid derivatives. Structure-activity relationships for excitatory amino acid antagonism and identification of potent and selective antagonists at the glycine site on the N-methyl-D-aspartate receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900121-5

7 January 2021

4-Amido-2-carboxytetrahydroquinolines. Structure-activity relationships for antagonism at the glycine site of the NMDA receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900121-5

7 January 2021

2-Carboxytetrahydroquinolines. Conformational and stereochemical requirements for antagonism of the glycine site on the NMDA receptor.

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900121-5

7 January 2021

3-Nitro-3,4-dihydro-2(1H)-quinolones. Excitatory amino acid antagonists acting at glycine-site NMDA and (RS)-alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900121-5

7 January 2021

Structural requirements for the development of potent N-methyl-D-aspartic acid (NMDA) receptor antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900121-5

7 January 2021

6,7-Dichloro-3-hydroxy-2-quinoxalinecarboxylic acid is a relatively potent antagonist at NMDA and kainate receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900121-5

7 January 2021

Thiokynurenates: a new group of antagonists of the glycine moduiatory site of the NMBA receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900121-5

7 January 2021

Synthesis and excitatory amino acid pharmacology of a series of heterocyclic-fused quinoxalinones and quinazolinones

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900121-5

7 January 2021

Anticonvulsant activity of a novel NMDA/glycine site antagonist, MDL 104,653, against kindled and sound-induced seizures

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900121-5

7 January 2021

4-substituted-3-phenylquinolin-2(1H)-ones: acidic and nonacidic glycine site N-methyl-D-aspartate antagonists with in vivo activity.

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900121-5

7 January 2021

3'-(Arylmethyl)- and 3'-(aryloxy)-3-phenyl-4-hydroxyquinolin-2(1H)-ones: orally active antagonists of the glycine site on the NMDA receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900121-5

7 January 2021

Structure-activity relationships of 4-hydroxy-3-nitroquinolin-2(1H)-ones as novel antagonists at the glycine site of N-methyl-D-aspartate receptors.

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900121-5

7 January 2021

3-(2-carboxyindol-3-yl)propionic acid derivatives: antagonists of the strychnine-insensitive glycine receptor associated with the N-methyl-D-aspartate receptor complex.

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900121-5

7 January 2021

3-(2-Carboxyindol-3-yl)propionic acid-based antagonists of the N-methyl-D-aspartic acid receptor associated glycine binding site

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900121-5

7 January 2021

Novel indole-2-carboxylates as ligands for the strychnine-insensitive N-methyl-D-aspartate-linked glycine receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900121-5

7 January 2021

Indole-2-carboxylates, novel antagonists of the N-methyl-D-aspartate (NMDA)-associated glycine recognition sites: in vivo characterization.

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900121-5

7 January 2021

Antagonist profile of 6,7-dichloro-3-hydroxy-2-quinoxalinecarboxylate at excitatory amino acid receptors in the neonatal rat spinal cord

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900121-5

7 January 2021

The glycine site on the NMDA receptor: structure-activity relationships and therapeutic potential

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900121-5

7 January 2021

Synthesis and structure-activity relationships of 1,2,3,4-tetrahydroquinoline-2,3,4-trione 3-oximes: novel and highly potent antagonists for NMDA receptor glycine site.

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900121-5

7 January 2021

Synthesis and structure-activity relationships of substituted 1,4-dihydroquinoxaline-2,3-diones: antagonists of N-methyl-D-aspartate (NMDA) receptor glycine sites and non-NMDA glutamate receptors.

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900121-5

7 January 2021

Binding of the radiolabeled glycine site antagonist [3H]MDL 105,519 to homomeric NMDA-NR1a receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900121-5

7 January 2021

Neuroprotective effects of RPR 104632, a novel antagonist at the glycine site of the NMDA receptor, in vitro.

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900121-5

7 January 2021

Anticonvulsant activity of antagonists for the NMDA-associated glycine binding site

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900121-5

7 January 2021

Facilitated brain uptake of 4-chlorokynurenine and conversion to 7-chlorokynurenic acid.

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900121-5

7 January 2021

N-methyl-D-aspartate antagonists for stroke and head trauma

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900121-5

7 January 2021

Cerestat and other NMDA antagonists in ischemic stroke

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900121-5

7 January 2021

Safety and tolerability of GV150526 (a glycine site antagonist at the N-methyl-D-aspartate receptor) in patients with acute stroke

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900121-5

7 January 2021

Nicotinylalanine increases cerebral kynurenic acid content and has anticonvulsant activity

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900121-5

7 January 2021

Modulation of Quinolinic and Kynurenic Acid Content in the Rat Brain: Effects of Endotoxins and Nicotinylalanine

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900121-5

7 January 2021

Modulation of the kynurenine pathway in search for new neuroprotective agents. Synthesis and preliminary evaluation of (m-nitrobenzoyl)alanine, a potent inhibitor of kynurenine-3-hydroxylase.

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900121-5

7 January 2021

Modulation of striatal quinolinate neurotoxicity by elevation of endogenous brain kynurenic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900121-5

7 January 2021

Comparison of the neurochemical and behavioral effects resulting from the inhibition of kynurenine hydroxylase and/or kynureninase

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900121-5

7 January 2021

(R,S)-3,4-dichlorobenzoylalanine (FCE 28833A) causes a large and persistent increase in brain kynurenic acid levels in rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900121-5

7 January 2021

Synthesis and biochemical evaluation of N-(4-phenylthiazol-2-yl)benzenesulfonamides as high-affinity inhibitors of kynurenine 3-hydroxylase.

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900121-5

7 January 2021

4-Halo-3-hydroxyanthranilic acids: Potent competitive inhibitors of 3-hydroxy-anthranilic acid oxygenase in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900121-5

7 January 2021

4-chloro-3-hydroxyanthranilate inhibits brain 3-hydroxyanthranate oxidase.

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900121-5

7 January 2021

4-Chloro-3-hydroxyanthranilate inhibits quinolinate production in the rat hippocampus in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900121-5

7 January 2021

Metabolism of L-tryptophan to kynurenate and quinolinate in the central nervous system: effects of 6-chlorotryptophan and 4-chloro-3-hydroxyanthranilate.

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900121-5

7 January 2021

In vivo models of cerebral ischemia: effects of parenterally administered NMDA receptor glycine site antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900121-5

7 January 2021

Electrophysiological characterisation of the antagonist properties of two novel NMDA receptor glycine site antagonists, L-695,902 and L-701,324

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900121-5

7 January 2021

Pharmacology of ACEA-1416: a potent systemically active NMDA receptor glycine site antagonist.

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900121-5

7 January 2021

ACEA 1021, a glycine site antagonist with minor psychotomimetic and amnestic effects in rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900121-5

7 January 2021

The N-methyl-D-aspartate (NMDA) receptor glycine site antagonist ACEA 1021 does not produce pathological changes in rat brain

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900121-5

7 January 2021

Neuronal injury associated with HIV-1: approaches to treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900121-5

7 January 2021

A glycine antagonist reduces ischemia-induced CA1 cell loss in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900121-5

7 January 2021

Glycine site antagonist attenuates infarct size in experimental focal ischemia. Postmortem and diffusion mapping studies

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900121-5

7 January 2021

Cerebrospinal fluid quinolinic acid concentrations are increased in acquired immune deficiency syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900121-5

7 January 2021

Increased ratio of quinolinic acid to kynurenic acid in cerebrospinal fluid of D retrovirus-infected rhesus macaques: relationship to clinical and viral status.

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900121-5

7 January 2021

NMDA-associated glycine binding site increases in schizophrenic brains.

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900121-5

7 January 2021

Excitatory amino acids: implications for psychiatric disorders research.

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900121-5

7 January 2021

Schizophrenia and glutamatergic transmission

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900121-5

7 January 2021

An open trial of glycine as an adjunct to neuroleptics in chronic treatment-refractory schizophrenics.

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900121-5

7 January 2021

R-(+)-HA-966, a glycine/NMDA receptor antagonist, selectively blocks the activation of the mesolimbic dopamine system by amphetamine

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2800%2900121-5

7 January 2021

10.1016/S0223-5234(00)00121-5

Identifiers

DOI

1 reference

29 July 2017

1 reference

PubMed ID

10758280